title: Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial.
authors.forename: Hans L
authors.initials: HL
authors.lastname: Tillmann
authors.forename: Thorsten
authors.initials: T
authors.lastname: Kaiser
authors.forename: Zoe
authors.initials: Z
authors.lastname: Fox
authors.forename: Schlomo
authors.initials: S
authors.lastname: Staszewski
authors.forename: Francesco
authors.initials: F
authors.lastname: Antunes
authors.forename: Antonella d'Arminio
authors.initials: Ad
authors.lastname: Monforte
authors.forename: Pietro
authors.initials: P
authors.lastname: Vernazza
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
authors.forename: Ulrik B
authors.initials: UB
authors.lastname: Dragsted
authors.forename: Jens D
authors.initials: JD
authors.lastname: Lundgren
mesh_terms: D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D001118:Argentina; D002986:Clinical Trials as Topic; D005060:Europe; D018178:Flaviviridae Infections / Q000150:complications* / Q000175:diagnosis; D029407:GB virus C / Q000276:immunology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006525:Hepatitis, Viral, Human / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D019438:Ritonavir / Q000627:therapeutic use*; D012698:Serologic Tests; D016896:Treatment Outcome; D014481:United States
chemical_list: D044966:Anti-Retroviral Agents; D017320:HIV Protease Inhibitors; D019438:Ritonavir